Spots Global Cancer Trial Database for Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Official Title: An Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study
Study ID: NCT01263353
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Bad Berka, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Marburg, , Germany
Novartis Investigative Site, Muenster, , Germany
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
